[go: up one dir, main page]

SG11201807188VA - Modified cells for immunotherapy - Google Patents

Modified cells for immunotherapy

Info

Publication number
SG11201807188VA
SG11201807188VA SG11201807188VA SG11201807188VA SG11201807188VA SG 11201807188V A SG11201807188V A SG 11201807188VA SG 11201807188V A SG11201807188V A SG 11201807188VA SG 11201807188V A SG11201807188V A SG 11201807188VA SG 11201807188V A SG11201807188V A SG 11201807188VA
Authority
SG
Singapore
Prior art keywords
international
pct
rule
chapel
hill
Prior art date
Application number
SG11201807188VA
Inventor
Gianpietro Dotti
Elisa Landoni
Abdijapar Shamshiev
Titus Kretzschmar
Miriam Droste
Douglas Philips
Original Assignee
Cell Medica Switzerland Ag
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Medica Switzerland Ag, Univ North Carolina Chapel Hill filed Critical Cell Medica Switzerland Ag
Publication of SG11201807188VA publication Critical patent/SG11201807188VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111 HO 11111011101011101111101111111001111101111 MI International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/147383 Al 31 August 2017 (31.08.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) C12N 5/10 (2006.01) kind A61K 35/17 (2015.01) AO, BZ, of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/019301 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, 24 February 2017 (24.02.2017) MD, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, ZA, ZM, ZW. TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: 16020057.2 25 February 2016 (25.02.2016) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: CELL MEDICA SWITZERLAND AG GM, [CH/CH]; Wagistrasse 27, 8952 Schlieren (CH). THE TZ, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, UNIVERSITY OF NORTH CAROLINA AT CHAPEL TJ, HILL [US/US]; 100 Europa Drive, Suite 430, Chapel Hill, DK, NC 27517 (US). LV, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, — (72) Inventors: DOTTI, Gianpietro; 111 Quaiview Dr., SM, Chapel Hill, NC 27516 (US). LANDONI, Elisa; 469 GW, KM, ML, MR, NE, SN, TD, TG). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Melanie Ct., Chapel Hill, NC 27514 (US). SHAMSHIEV, Declarations under Rule 4.17: Abdij apar; Buchzelgstrasse 64, 8053 Zurich (CH). — of inventorship (Rule 4.17(iv)) KRETZSCHMAR, Titus; Sonnhaldenstrasse 63b, 6331 Hunenberg (CH). DROSTE, Miriam; Grunaustrasse 14, Published: = 8953 Diietikon (CH). PHILIPS, Douglas; c/o Cell Medica with Switzerland AG, Wagistrasse 27, 8952 Schlieren (CH). international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) — (74) Agents: ELMORE, Carolyn, S. et al.; Elmore Patent Law = Group, P.C., 484 Groton Rd., Westford, MA 01886 (US). = = = = = = = = = Il M GC M IN 7r 11 IN 11 © (54) Title: MODIFIED CELLS FOR IMMUNOTHERAPY ei , (57) : The present invention relates to engineered immune cells expressing antigen receptors, such as a T cell receptor (TCR) or a chimeric antigen receptor (CAR), as well as antibody targeting PD-Ll. Also provided are related nucleic acids, vectors, compositions and method for enhancing the immune response towards cancers and pathogens.
SG11201807188VA 2016-02-25 2017-02-24 Modified cells for immunotherapy SG11201807188VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16020057 2016-02-25
PCT/US2017/019301 WO2017147383A1 (en) 2016-02-25 2017-02-24 Modified cells for immunotherapy

Publications (1)

Publication Number Publication Date
SG11201807188VA true SG11201807188VA (en) 2018-09-27

Family

ID=55446573

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201807188VA SG11201807188VA (en) 2016-02-25 2017-02-24 Modified cells for immunotherapy
SG11201807187XA SG11201807187XA (en) 2016-02-25 2017-02-24 Binding members to pd-l1

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201807187XA SG11201807187XA (en) 2016-02-25 2017-02-24 Binding members to pd-l1

Country Status (12)

Country Link
US (3) US11434294B2 (en)
EP (3) EP4086285A1 (en)
JP (3) JP7082574B2 (en)
KR (2) KR20180111870A (en)
CN (3) CN108884164B (en)
AU (2) AU2017224843A1 (en)
BR (2) BR112018067696A2 (en)
CA (2) CA3014067A1 (en)
ES (1) ES2903408T3 (en)
RU (2) RU2018128462A (en)
SG (2) SG11201807188VA (en)
WO (2) WO2017144681A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (en) * 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
PE20181300A1 (en) 2015-11-02 2018-08-09 Five Prime Therapeutics Inc CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF CANCER
JP7082574B2 (en) 2016-02-25 2022-06-08 セル メディカ スイッツァランド アーゲー Modified cells for immunotherapy
TWI755395B (en) 2016-05-13 2022-02-21 美商再生元醫藥公司 Combination of anti-pd-1 antibodies and radiation to treat cancer
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
EP4032544A3 (en) 2016-12-08 2022-12-21 Immatics Biotechnologies GmbH Novel t cell receptors and immune therapy using the same
JP7275043B2 (en) 2016-12-16 2023-05-17 ビー－モーゲン・バイオテクノロジーズ，インコーポレーテッド Enhanced hAT Family Transposon-Mediated Gene Transfer and Related Compositions, Systems and Methods
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3054289A1 (en) 2017-02-21 2018-08-30 Regeneron Pharmaceuticals, Inc. Anti-pd-1 antibodies for treatment of lung cancer
US11446332B2 (en) 2017-04-13 2022-09-20 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN110546509A (en) 2017-04-28 2019-12-06 戊瑞治疗有限公司 Methods of treatment with CD80 extracellular domain polypeptides
SG11202005750TA (en) * 2017-12-20 2020-07-29 Poseida Therapeutics Inc Vcar compositions and methods for use
CN111684061B (en) 2018-01-19 2024-07-30 美天施生物科技有限两合公司 Regulatory T cells expressing chimeric antigen receptors
CN112119099A (en) 2018-03-02 2020-12-22 Cdr-生物科技股份有限公司 Trispecific antigen binding proteins
US12054548B2 (en) * 2018-03-29 2024-08-06 Adagene, Inc. Anti-PD-L1 antibodies and use thereof
CA3102744A1 (en) * 2018-06-04 2019-12-12 Diatheva S.R.L. Anti-cd99 diabody or igg antibody and uses thereof
EP3810764A2 (en) 2018-06-21 2021-04-28 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11945864B2 (en) 2018-06-29 2024-04-02 Y-Biologics Inc. Monoclonal antibody specifically binding to LAG-3 and use thereof
JP7617839B2 (en) 2018-07-09 2025-01-20 プレシゲン，インコーポレイテッド Fusion constructs and methods of use thereof
EP3860716A2 (en) * 2018-10-01 2021-08-11 Adicet Bio Inc. Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US10993967B2 (en) 2018-10-17 2021-05-04 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2020118094A1 (en) * 2018-12-06 2020-06-11 Guangdong Tcrcure Biopharma Technology Co., Ltd. Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
WO2020135559A1 (en) * 2018-12-26 2020-07-02 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
CN109652379B (en) * 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 CD7 chimeric antigen receptor modified NK-92MI cell and application thereof
CN111454358A (en) * 2019-01-18 2020-07-28 四川科伦博泰生物医药股份有限公司 Chimeric antigen receptor and application thereof
US11440948B2 (en) * 2019-01-28 2022-09-13 Xyphos Biosciences Inc. Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on car-cells
AU2020235395A1 (en) * 2019-03-08 2021-09-02 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR
JP2022527081A (en) * 2019-03-26 2022-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Chimeric antigen receptor-modified T cells (CAR-T) for the treatment of hematological and solid cancers
CN110402892A (en) * 2019-04-30 2019-11-05 梁廷波 Selectivity knocks out the method for building up of the spontaneous cancer of pancreas mouse model of 1 molecule of pancreatic epithelial cells programmed death ligand
CN112079924B (en) * 2019-06-12 2024-02-06 苏州工业园区唯可达生物科技有限公司 PD-L1 targeted binding agents and their uses
CN114502596A (en) * 2019-07-02 2022-05-13 泰利克斯国际有限公司 Antibodies to CAIX with reduced affinity for neonatal Fc receptor
WO2021057906A1 (en) * 2019-09-25 2021-04-01 科济生物医药（上海）有限公司 Immune effector cell expressing il-15
PH12022551078A1 (en) * 2019-11-04 2024-06-19 Regeneron Pharma Combination therapy to treat brain cancer
RU2733430C1 (en) * 2019-11-19 2020-10-01 Общество с ограниченной ответственностью «Реал Таргет» Creation of conjugates of gd2-specific antibodies and fragments of gd2-specific antibodies with preparations
CN115925976A (en) * 2019-11-21 2023-04-07 博生吉医药科技(苏州)有限公司 CD7-CAR-T cell and preparation and application thereof
JP2023504271A (en) * 2019-12-02 2023-02-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Antibodies against PD-L1 and methods of use thereof
WO2021130535A2 (en) * 2019-12-28 2021-07-01 Shanghai Cell Therapy Group Company Co., Ltd. Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules
EP3878858A1 (en) * 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
CN120060368A (en) * 2020-03-23 2025-05-30 株式会社库利金 Structure of oncolytic viruses comprising bispecific nucleic acid molecules
JP2023526605A (en) * 2020-05-14 2023-06-22 ヴィルトゥオーソ ビンコ，インク． Humanized CD38 and ICAM1 antibodies and uses thereof
WO2021252654A1 (en) * 2020-06-11 2021-12-16 Innovative Cellular Therapeutics Holdings, Ltd. Cell/gene therapies targeting mage-a4 peptide
US20230227557A1 (en) * 2020-06-25 2023-07-20 Promab Biotechnologies, Inc. Pd-l1-specific antibody and anti-pd-l1-car-t cells
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
IL302568A (en) * 2020-11-04 2023-07-01 Senti Biosciences Inc protein cargo release
CN112375743A (en) * 2020-11-20 2021-02-19 山东省医学科学院附属医院 Secretory HER2 antigen-targeted chimeric antigen receptor T cell and application thereof
AU2021387801A1 (en) * 2020-11-30 2023-06-29 Blaze Bioscience, Inc. Pd-l1 binding peptides and peptide complexes and methods of use thereof
CN113234152B (en) * 2021-06-03 2023-05-02 天津科技大学 Programmed death receptor-ligand 1 (PD-L1) specific binding polypeptide and application thereof
US20240139321A1 (en) * 2021-07-01 2024-05-02 Ningbo T-Maximum Biopharmaceuticals Co., Ltd. Universal car-t cell targeting gd2, preparation method therefor, and application thereof
EP4376887A2 (en) * 2021-07-30 2024-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
WO2023019240A2 (en) 2021-08-13 2023-02-16 Inovio Pharmaceuticals Inc. Combination therapy to treat brain cancer
CN118176017A (en) * 2021-10-26 2024-06-11 正大天晴药业集团股份有限公司 Combined medicine for treating tumor
CN116410331B (en) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 CS 1-targeted chimeric antigen receptor, BCMA/CS 1-targeted bispecific chimeric antigen receptor and application thereof
AU2023213978A1 (en) * 2022-01-28 2024-08-15 The University Of North Carolina At Chapel Hill Natural killer t-cells and methods of using the same
CN118005806A (en) * 2024-02-08 2024-05-10 北京市眼科研究所 Chimeric antigen receptor, microglia expressing chimeric antigen receptor differentiated from human pluripotent stem cells and their application

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237113B4 (en) 1992-11-03 2006-10-12 "Iba Gmbh" Peptides and their fusion proteins, expression vector and method of producing a fusion protein
DE19641876B4 (en) 1996-10-10 2011-09-29 Iba Gmbh streptavidin muteins
DE10113776B4 (en) 2001-03-21 2012-08-09 "Iba Gmbh" Isolated streptavidin-binding, competitively elutable peptide, this comprehensive fusion peptide, nucleic acid coding therefor, expression vector, methods for producing a recombinant fusion protein and methods for detecting and / or obtaining the fusion protein
JP4249013B2 (en) 2001-07-31 2009-04-02 佑 本庶 Substance with specificity for PD-1
PT2332989E (en) 2002-05-22 2015-08-05 Esbatech Alcon Biomed Res Unit Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
JP5563194B2 (en) 2004-06-29 2014-07-30 イムノコア リミテッド Cells expressing modified T cell receptors
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
CN101849001B (en) 2007-06-25 2014-07-16 艾斯巴技术-诺华有限责任公司 Methods of modifying antibodies, and modified antibodies with improved functional properties
RU2514658C2 (en) 2008-06-25 2014-04-27 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Optimising solubility of immunobinders
KR102007492B1 (en) 2008-06-25 2019-08-05 에스바테크 - 어 노바티스 컴파니 엘엘씨 Humanization of rabbit antibodies using a universal antibody framework
RU2636023C2 (en) 2008-12-09 2017-11-17 Дженентек, Инк. Antibodies to pd-l1 and their application for t-cells function strengthening
KR101790767B1 (en) 2009-11-24 2017-10-26 메디뮨 리미티드 Targeted binding agents against b7-h1
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
EP3692794A1 (en) 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
HUE051954T2 (en) 2011-11-28 2021-03-29 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US9175082B2 (en) * 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
MX368513B (en) 2012-06-06 2019-10-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for the diagnosis, prognosis and treatment of lung cancer metastasis.
MY175869A (en) 2013-02-26 2020-07-14 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
HK1218549A1 (en) 2013-06-26 2017-02-24 Numab Therapeutics AG Novel antibody frameworks
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
EP3074025A1 (en) 2013-11-27 2016-10-05 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
TWI680138B (en) 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
ES2939760T3 (en) * 2014-03-15 2023-04-26 Novartis Ag Cancer treatment using a chimeric receptor for antigens
CA2950763A1 (en) * 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
AU2015288232B2 (en) 2014-07-11 2020-10-15 Ventana Medical Systems, Inc. Anti-PD-L1 antibodies and diagnostic uses thereof
WO2016034666A1 (en) 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
US20170281683A1 (en) 2014-09-26 2017-10-05 Baylor College Of Medicine Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
US20170335290A1 (en) 2014-10-31 2017-11-23 Baylor College Of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
KR20170090506A (en) 2014-12-19 2017-08-07 다나-파버 캔서 인스티튜트 인크. Chimeric antigen receptors and methods for their use
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
CN105331585A (en) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent
JP7082574B2 (en) 2016-02-25 2022-06-08 セル メディカ スイッツァランド アーゲー Modified cells for immunotherapy

Also Published As

Publication number Publication date
JP7082574B2 (en) 2022-06-08
JP7080819B2 (en) 2022-06-06
BR112018067696A2 (en) 2019-01-08
EP3420001A1 (en) 2019-01-02
CN116082505A (en) 2023-05-09
ES2903408T3 (en) 2022-04-01
US20190055312A1 (en) 2019-02-21
US20190048085A1 (en) 2019-02-14
CN108884164B (en) 2022-12-27
JP2019513009A (en) 2019-05-23
WO2017144681A1 (en) 2017-08-31
SG11201807187XA (en) 2018-09-27
CN108699153A (en) 2018-10-23
KR20190003938A (en) 2019-01-10
CA3014067A1 (en) 2017-08-31
US11434294B2 (en) 2022-09-06
JP2022116230A (en) 2022-08-09
US20230235061A1 (en) 2023-07-27
JP2019515646A (en) 2019-06-13
WO2017147383A1 (en) 2017-08-31
AU2017224843A1 (en) 2018-08-23
RU2018128462A (en) 2020-03-25
EP3420000A1 (en) 2019-01-02
CN108699153B (en) 2022-09-23
KR20180111870A (en) 2018-10-11
AU2017223846A1 (en) 2018-08-23
EP4086285A1 (en) 2022-11-09
CN108884164A (en) 2018-11-23
WO2017147383A8 (en) 2018-11-15
BR112018067698A2 (en) 2019-01-08
EP3420001B1 (en) 2021-12-01
RU2018128464A (en) 2020-03-25
CA3014001A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
SG11201807188VA (en) Modified cells for immunotherapy
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201903825SA (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201909331UA (en) Antigen-specific immune effector cells
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201807437XA (en) Antibodies specific to human poliovirus receptor (pvr)
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201806496SA (en) Antigen binding proteins that bind pd-l1